**Author details**

Takahito Nakajima1 \* and Oyunbold Lamid-Ochir1,2

1 Gunma Graduate School of Medicine, Maebashi, Japan

2 National First Central Hospital of Mongolia, Ulaanbaatar, Mongolia

\*Address all correspondence to: sojin@gunma-u.ac.jp

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**63**

*Current Clinical Issues: Deposition of Gadolinium Chelates*

gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Investigative Radiology. 2008;**43**:817-828. DOI: 10.1097/RLI.0b013e3181852171

[10] Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: Structure, dynamics, and applications. Chemical Reviews. 1999;**99**:2293-2352. DOI:

[11] Bellin M. MR contrast agents, the old and the new. European Journal of

[12] Grobner T. Erratum: Gadolinium—A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? (Nephrology, Dialysis, Transplantation (2006;**21**:1104-1108)). Nephrology, Dialysis, Transplantation. 2006;**21**:1745.

Radiology. 2006;(3):314-323

DOI: 10.1093/ndt/gfl294

[13] Thomsen HS, Marckmann P, Logager VB. Nephrogenic systemic fibrosis (NSF): A late adverse reaction to some of the gadolinium based contrast agents. Cancer Imaging. 2007;**7**:130-137. DOI: 10.1102/1470-7330.2007.0019

[14] Sethi R, MacKeyev Y, Wilson LJ. The Gadonanotubes revisited: A new frontier in MRI contrast agent design. Inorganica Chimica Acta. 2012;**393**: 165-172. DOI: 10.1016/j.ica.2012.07.004

[15] Runge VM. Macrocyclic versus linear gadolinium chelates. Investigative Radiology. 2015;**50**:811. DOI: 10.1097/

[16] Tóth É, Helm L, Merbach AE. In: Krause W, editor. Relaxivity of MRI Contrast Agents BT—Contrast Agents I: Magnetic Resonance Imaging. Berlin, Heidelberg: Springer Berlin Heidelberg; 2002. pp. 61-101. DOI:

RLI.0000000000000229

10.1007/3-540-45733-X\_3

10.1021/cr980440x

*DOI: http://dx.doi.org/10.5772/intechopen.91260*

[1] Haacke EM, Brown RW, Thompson MR, Venkatesan R. Magnetic Resonance

[2] Zhou Z, Lu Z-R. Gadolinium-based contrast agents for magnetic resonance cancer imaging. Wiley Interdisciplinary Reviews Nanomedicine Nanobiotechnology. 2013;**5**:1-18. DOI: 10.1002/

[3] Morris SA, Slesnick TC. Magnetic resonance imaging. Visual Guide to Neonatal Cardiology. 2018:104-108

[4] Runge VM. Chapter 14. Contrast media BT-clinical MRI. Clinical MRI.

[5] Kanda T, Nakai Y, Oba H, Toyoda K, Kitajima K, Furui S. Gadolinium deposition in the brain. Magnetic Resonance Imaging. 2016;**34**:1346-1350.

DOI: 10.1016/j.mri.2016.08.024

DOI: 10.1016/j.aca.2012.12.007

2001;**22**:1357-1361

[7] Rai AT, Hogg JP. Persistence of Gadolinium in CSF: A diagnostic pitfall in patients with end-stage renal disease. American Journal of Neuroradiology.

[8] Nordenskiold L, Laaksonen A, Kowalewski J. Applicability of the Solomon-Bloembergen equation to the study of paramagnetic transition metal-water complexes. An ab initio SCF-MO study. Journal of the American Chemical Society. 1982;**104**:379-382.

DOI: 10.1021/ja00366a002

[9] Frenzel T, Lengsfeld P, Schirmer H, Hütter J, Weinmann HJ. Stability of

[6] Telgmann L, Sperling M, Karst U. Determination of gadolinium-based MRI contrast agents in biological and environmental samples: A review. Analytica Chimica Acta. 2013;**764**:1-16.

Imaging: Physical Principles and Sequence Design. Vol. 82. New York:

**References**

Wiley-Liss; 1999

wnan.1198

2002:454-472

*Current Clinical Issues: Deposition of Gadolinium Chelates DOI: http://dx.doi.org/10.5772/intechopen.91260*
